病例报告：艾加莫德是治疗眼肌型重症肌无力的一种新的治疗选择：2例报告
Case report: Efgartigimod is a novel therapeutic option for ocular myasthenia gravis: a report of 2 cases.
作者信息
Ma Tianying, Zhu Ying, Zhu Ruixia
机构信息
Department of Neurology, The First Affiliated Hospital of China Medical University, Shenyang, China.
出版信息
Front Immunol. 2025 Jan 13;15:1497398. doi: 10.3389/fimmu.2024.1497398. eCollection 2024.
INTRODUCTION
Efgartigimod has been approved for the treatment of acetylcholine receptor antibodies-positive generalized myasthenia gravis (AChR-Ab+gMG), but its efficacy in patients with ocular myasthenia gravis (OMG) is not known.
CASE PRESENTATION
We describe 2 cases of patients with AChR-Ab+ OMG who showed unfavorable responses to corticosteroids and tacrolimus. Within 2 weeks of initiating efgartigimod, both patients showed rapid improvement and minimal symptom expression was achieved in weeks 3 to 4, which was maintained up to week 12.
CONCLUSION
The 2 cases described herein provide preliminary evidence for the effectiveness of efgartigimod for the treatment of OMG for patients who do not respond or are intolerant to conventional medications. Large-scale studies are needed to confirm these findings.
引言
艾加莫德已被批准用于治疗乙酰胆碱受体抗体阳性的全身型重症肌无力（AChR-Ab+gMG），但其对眼肌型重症肌无力（OMG）患者的疗效尚不清楚。
病例报告
我们描述了2例AChR-Ab+OMG患者，他们对皮质类固醇和他克莫司反应不佳。在开始使用艾加莫德的2周内，两名患者均显示出快速改善，在第3至4周症状表达降至最低，并维持到第12周。
结论
本文所述的2例病例为艾加莫德治疗对传统药物无反应或不耐受的OMG患者的有效性提供了初步证据。需要进行大规模研究来证实这些发现。
Zotero 插件